3B Blackbio DX Ltd
₹ 1,978
-0.52%
15 Jan
11:50 a.m.
About
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Key Points
- Market Cap ₹ 1,698 Cr.
- Current Price ₹ 1,978
- High / Low ₹ 2,350 / 695
- Stock P/E 39.4
- Book Value ₹ 287
- Dividend Yield 0.16 %
- ROCE 21.0 %
- ROE 15.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 17.2%
Cons
- Company has high debtors of 179 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 89 | |
| 19 | 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 43 | |
| Operating Profit | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 46 |
| OPM % | 6% | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% | 51% |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 14 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 59 |
| Tax % | 34% | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | 28% | |
| 0 | 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 43 | |
| EPS in Rs | 0.62 | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.40 | 50.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 8% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 26% |
| 3 Years: | -31% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 56% |
| 5 Years: | 44% |
| 3 Years: | -34% |
| TTM: | 61% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 70% |
| 5 Years: | 85% |
| 3 Years: | 62% |
| 1 Year: | 158% |
| Return on Equity | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 33% |
| 3 Years: | 17% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 |
| Reserves | 3 | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 238 |
| 6 | 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 1 | |
| 7 | 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 22 | |
| Total Liabilities | 23 | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 269 |
| 4 | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 133 |
| 19 | 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 129 | |
| Total Assets | 23 | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 269 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | 0 | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | |
| 0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | |
| -0 | 0 | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | |
| Net Cash Flow | -1 | 0 | -0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 220 | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 | 179 |
| Inventory Days | 149 | 120 | 145 | 143 | 175 | 164 | 141 | |||||
| Days Payable | 220 | 189 | 218 | 203 | 186 | 69 | 66 | |||||
| Cash Conversion Cycle | 149 | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 296 | 253 |
| Working Capital Days | 214 | 218 | 274 | 312 | 377 | 308 | 351 | 302 | 67 | 169 | 248 | 216 |
| ROCE % | 8% | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% | 21% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Jan - Certificate under Reg 74 (5) of SEBI (DP) Regulations for the quarter ended December 31 , 2024
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
3 Jan - Company received a tax demand notice from Income Tax Department.
- Closure of Trading Window 24 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov 2024 - Newspaper Advertisement- Regulation 47 of SEBI (LODR) Regulations, 2015
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Nov 2024
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit